HALOZYME THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HALO in the last 7 days.
Halozyme Therapeutics (HALO) stock rose 36.4% in the past month due to strong Q2 2026 results and raised full-year guidance. The company's ENHANZE drug-delivery technology, licensed to partners like J&J and Roche, drove revenue growth. Royalty revenues increased 46.7% YoY to $373.8M, and total revenues are now projected at $1.84-$1.91B for 2026.
BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
Halozyme (HALO) appointed Dannielle Appelhans to its board, citing her biotech and pharma leadership experience. CEO Helen Torley sold 60,000 shares for $6.28M. HALO's stock closed at $107.62, up 2.60%.
Recent HALO coverage spans earnings, financial news and insider activity.
In the last 30 days, HALO insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($6.4M). The most active reporter was Torley Helen, PRESIDENT AND CEO, with 11 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Guidance lift and strong royalty growth suggest near‑term upside for HALO.
Strong top‑line growth and beat suggest upside potential.
Board addition may support growth; insider sell could signal short-term pressure.
Large insider sell by the CEO may signal reduced confidence and could pressure the stock lower.
Board appointment is a governance and execution-signal catalyst, but the release provides no new financial targets, clinical data, or deal terms.
alphai scores every news story that mentions HALO with an AI model for sentiment and relevance, and aggregates insider trades from HALOZYME THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Halozyme Therapeutics (HALO) stock rose 36.4% in the past month due to strong Q2 2026 results and raised full-year guidance. The company's ENHANZE drug-delivery technology, licensed to partners like J&J and Roche, drove revenue growth. Royalty revenues increased 46.7% YoY to $373.8M, and total revenues are now projected at $1.84-$1.91B for 2026.
2 min readBioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
3 min readHalozyme (HALO) appointed Dannielle Appelhans to its board, citing her biotech and pharma leadership experience. CEO Helen Torley sold 60,000 shares for $6.28M. HALO's stock closed at $107.62, up 2.60%.
1 min readTorley Helen (PRESIDENT AND CEO) sold 60,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $104.59 ($98.96–$107.76, $6.28M total) across 11 trades over 2026-08-17 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readHalozyme Therapeutics (HALO) appointed Dannielle Appelhans to its board. Appelhans has 20+ years of biotech and pharma experience, including CEO roles at COUR Pharmaceuticals and Rubius Therapeutics. She brings expertise in operations and manufacturing, aligning with Halozyme's growth strategy for ENHANZE, Hypercon, and Surf Bio technologies. Appelhans' leadership in scaling operations and executing partnerships is expected to benefit Halozyme's growth and shareholder value.
3 min readHALOZYME THERAPEUTICS, INC. (HALO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Com
2 min readHalozyme Therapeutics (HALO) and Incyte (INCY) announced a global collaboration using Incyte’s INCA033989 subcutaneous formulation with Halozyme’s ENHANZE delivery. Halozyme will receive upfront, milestones and royalties, while Incyte can add two targets. The article also compares Q2 2026 results and guidance for both companies.
6 min readHalozyme Therapeutics (HALO) reported Q2 2026 revenue of $481.0 million, up 48%, driven by royalty revenue of $307.7 million and higher product sales. The company raised 2026 guidance for total revenue to $1.835-$1.91 billion and royalty revenue to $1.22-$1.245 billion. It repurchased $332.8 million of shares and guided non-GAAP EPS to $8.65-$9.00.
6 min readHalozyme Therapeutics (NASDAQ:HALO) shares rose about 18% after the company reported Q2 adjusted EPS of $2.28 on revenue of $481 million, beating consensus of $1.82 and $404.3 million. Halozyme cited 47.7% YoY revenue growth from ENHANZE royalties and milestones. It raised full-year guidance to $1.87B revenue and $8.83 adjusted EPS midpoint.
4 min readBiotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min read
